Calvical

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calvical

Quick Facts

Property Description
Active ingredients Calcium Carbonate, Dihydrotachysterol
Form Oral Tablet or Capsule
Pharmacological class Calcium Supplement, Vitamin D Analog
Common purpose Mineral balance and calcium homeostasis support
Origin Inorganic Mineral Salt and Synthetic Analog

What Type of Medicine is Calvical?

Calvical is a pharmaceutical combination medication classified as an oral Calcium Supplement and a Vitamin D Analog. This dual classification means the product is engineered to deliver both a foundational mineral source and a mechanism to ensure its proper utilization. The preparation is intended for oral administration and is routinely provided in an oral tablet or capsule dosage form.

The core objective of combining these two pharmacological classes is to provide support for calcium homeostasis, a strategy utilized for stabilizing essential mineral levels. The combination ensures a more comprehensive approach to managing mineral balance compared to single-ingredient supplements. Vitamin D analogs are used to enhance the absorption of calcium from the gut, acting as agents in managing mineral disorders. As such, the medication is designed to maximize the uptake of the mineral it supplies.


Composition and Origin: The Active Ingredients

The active ingredients in Calvical are Calcium Carbonate and Dihydrotachysterol. These two components have distinct chemical origins: Calcium Carbonate is an inorganic mineral salt, whereas Dihydrotachysterol is officially recognized as a synthetic analog of Vitamin D2.

The Calcium Carbonate component provides the essential mineral elemental calcium (Ca^2+), which is critical for skeletal structure and numerous biological signaling pathways. Dihydrotachysterol is included because it requires fewer metabolic activation steps in the body compared to natural Vitamin D, allowing it to directly enhance the intestinal absorption of both calcium and phosphate. This unique metabolic efficiency makes the formulation relevant for patient groups where the full activation of natural Vitamin D may be compromised.


What is the General Purpose of Calvical?

The general purpose of Calvical is to correct and support the body’s overall calcium and mineral balance. By simultaneously supplying calcium and boosting its absorption via the Dihydrotachysterol component, the medication works to ensure that sufficient mineral is available for vital physiological functions.

This dual-action mechanism is intended for sustaining the health of the skeleton, promoting proper nerve conduction, and maintaining effective muscle function. Calcium is the most abundant mineral in the body and is necessary for nearly all organ systems to function properly. The medication addresses a core nutritional and physiological requirement, a use consistent with pharmacological application across various patient populations. The drug’s composition provides a strategy for correcting significant mineral deficits and stabilizing appropriate levels of circulating calcium.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus: Dihydrotachysterol

What side effects are possible with Calvical?

Possible Side Effects and Safety Information

The safety profile of Calvical (Calcium Carbonate + Dihydrotachysterol) is officially classified by regulatory documents into system-organ classes and frequency categories, focusing on effects related to mineral regulation and the digestive system.


Frequency and Systemic Adverse Reactions

Adverse reactions are formally grouped by the body system affected and frequency:

  • Common Reactions: Adverse effects frequently reported involve Gastrointestinal Disorders, including constipation, flatulence, and abdominal pain. Nausea and dyspepsia are also listed in this category.
  • Uncommon Reactions: These typically involve Metabolism and Nutrition Disorders, such as Hypercalcemia (high blood calcium levels) and Hypercalciuria (high urinary calcium excretion).
  • Rare Reactions: Less common effects include Polyuria (increased urination) and Milk-alkali syndrome, documented in the context of high doses.

Serious Safety Considerations

The primary systemic concern documented in regulatory sources is the potential for significant mineral imbalance leading to serious adverse reactions. These include Hypercalcemic crisis, which arises from uncontrolled calcium levels, and Nephrocalcinosis (calcium deposits in the kidney), which may be associated with prolonged Hypercalciuria. The risk of these systemic effects is officially noted as being more likely with dose escalation or prolonged exposure to the medication.


Safety Restrictions and Special Populations

Calvical is subject to explicit safety restrictions (contraindications) and should not be used in individuals with pre-existing conditions involving elevated mineral levels, such as Hypercalcemia, Hypercalciuria, Nephrolithiasis (kidney stones), or severe renal impairment. Patients with renal impairment or those in the geriatric population are documented as being at an increased risk of Hypercalcemia due to potentially reduced mineral excretion.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Calvical, a combination of a Calcium Salt and a Vitamin D Analog, is strictly defined by the toxic effect known as Hypercalcemia (abnormally high blood calcium levels).

Documented early clinical manifestations of Hypercalcemia include a spectrum of non-specific symptoms such as anorexia, nausea, vomiting, polyuria (excessive urination), polydipsia (excessive thirst), lethargy, and muscle weakness. More severe manifestations officially listed are confusion, ataxia, and vertigo.

The official labeling emphasizes that overdose can lead to severe and life-threatening outcomes. These complications include major damage to physiological systems, resulting in cardiac arrhythmias, renal insufficiency, potentially progressing to irreversible organ damage, coma, or death. Patients with pre-existing renal impairment are officially noted to be at increased risk for these severe complications.

Due to these significant, documented risks, regulators mandate clear and immediate action: if an overdose is suspected or confirmed, users must stop using the medication immediately and seek immediate medical attention. Official documents confirm that treatment is symptomatic and supportive, often requiring clinical procedures like intravenous hydration, as no specific antidote is known.

Therapeutic Uses of Calvical

Calvical, containing calcium carbonate, is commonly used across conditions presenting with acute episodes related to gastrointestinal discomfort and in therapeutic domains where additional symptomatic support is needed. Generally, these applications are categorized into two primary areas.

One primary area of use involves addressing symptoms related to heightened physiological activity, such as heartburn, acid indigestion, and upset stomach. Calvical helps as an antacid, providing supportive symptomatic relief for issues related to stomach acidity.

The second area is considered relevant for systemic support. It is relevant for easing the manifestations of low blood calcium levels and is applied to help with maintaining appropriate blood calcium levels, a common need in conditions where functional stability becomes affected, like osteoporosis. Additionally, the compound is considered relevant to bind with phosphate, a function used in contexts involving heightened systemic burden, such as in chronic kidney disease. The primary uses cover a range of applications, including antacid relief, calcium supplementation, and phosphate binding. Calvical may generally contribute to easing the overall symptom load related to these contexts, and it may assist with day-to-day comfort during symptomatic periods.

Quick Facts: Applied for managing symptoms related to physical discomfort (antacid use) and assisting with functional stability (supplement use).

Regulatory References

  1. NIH MedlinePlus overview of Calcium Carbonate

Eligibility and Restrictions for Use

Who can and cannot use Calvical?

Eligibility for Calvical, which contains Calcium Carbonate and the potent Vitamin D analog Dihydrotachysterol, is strictly defined by regulatory documents based on pre-existing mineral balance and renal function. Individuals without these documented restrictions, primarily Adults and the Elderly, are considered the approved population.

Ineligible and Restricted Populations

Category Regulatory Status (Absolute Contraindication)
Mineral Levels Hypercalcaemia (high blood calcium) and Hypervitaminosis D are prohibited.
Organ Dysfunction Severe Renal Impairment and active Nephrolithiasis (kidney stones) are contraindicated.
Physiological States Breastfeeding mothers are prohibited from use, and pregnancy use is restricted—only justified if the benefit outweighs potential fetal risk.
Age Groups Use in Children and Adolescents is generally not established or not recommended.

Conditional Use Requirements

Patients with mild to moderate renal impairment or conditions like Sarcoidosis are eligible only under conditional use. The official labeling requires careful medical supervision, including regular monitoring of serum calcium and phosphate concentrations to prevent adverse outcomes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Calvical is defined by the regulatory-documented interaction patterns of its two components: Calcium Carbonate and Dihydrotachysterol. These documented interactions result in specific co-administration restrictions defined by regulatory authorities.

Officially Documented Restrictions

Co-administration is formally restricted or contraindicated in certain combinations. Eltrombopag is documented as contraindicated due to the severe reduction in its plasma exposure caused by the calcium component. Similarly, IV Ceftriaxone is restricted from use with any calcium-containing solutions due to the risk of precipitate formation.

Pharmacodynamic and Toxicity Risk

Combinations with other agents may increase toxicity risk. The use of Calvical with other Vitamin D Analogs or Thiazide Diuretics presents an additive pharmacodynamic effect, leading to a high risk of hypercalcemia and related adverse outcomes. Co-administration with Cardiac Glycosides (e.g., Digoxin) increases the risk of ventricular arrhythmias due to elevated serum calcium concentrations.

Exposure and Timing Constraints

The Calcium Carbonate component can reduce the oral absorption of other medicines, necessitating mandatory administration separation. Medicines such as Oral Tetracyclines, Bisphosphonates, and Levothyroxine must be taken at least 30 minutes or 2 hours apart from Calvical to maintain their intended systemic exposure. Substances like Bile Acid Sequestrants and Grapefruit Juice are noted to alter the plasma concentrations of the Dihydrotachysterol component. Regulatory documentation also notes that the activity of Dihydrotachysterol may be altered in cases of hepatic impairment.

Mechanism of Action

How Calvical Works

Calvical functions as a specific ligand within domains involving nuclear receptor-mediated signaling. It selectively targets the Vitamin D Receptor (VDR), forming a heterodimeric complex with the Retinoic Acid X receptor (RXR). This complex translocates to the nucleus and acts as a transcription factor, interacting with specific DNA response elements to modulate the initiation or suppression of genetic signaling sequences.

This molecular activity initiates key pathway effects within the calcium and phosphate homeostasis systems. Calvical promotes the enhancement of intestinal absorption of dietary calcium and phosphate and drives the increase of renal tubular reabsorption of calcium. These actions culminate in the regulation of plasma calcium and phosphate concentrations.

Furthermore, Calvical influences systems where targeted pathway adjustment is required, specifically by modulating the activity of certain cytokines and altering processes related to cell proliferation and differentiation, thereby influencing cellular pathway activity within targeted biological systems.

Dosage and Administration Information

How to Use Calvical

The usage of Calvical, a combination product containing Calcium Carbonate and the Vitamin D Analog Dihydrotachysterol, is defined by a structured, standardized protocol focused on long-term mineral balance. Administration is strictly through the oral route as an oral tablet or capsule.


Administration Protocol and Dosing

Treatment is typically divided into two distinct periods for the Dihydrotachysterol component. An initial loading dose in the range of 0.8 mg to 2.4 mg daily is used for a short duration (several days). This is followed by a long-term maintenance dose that is reduced to 0.2 mg to 1.0 mg daily. The Dihydrotachysterol dose is administered once daily.

Critically, the Vitamin D analog requires concurrent and adequate elemental calcium intake to function correctly, which is typically provided by the Calcium Carbonate component. To optimize absorption, this calcium portion is usually administered in divided doses throughout the day, often taken with meals.


Procedural and Monitoring Requirements

Dose establishment is a highly supervised process. The dose of Dihydrotachysterol is carefully titrated based on frequent measurement of serum calcium levels, often with adjustments made only at 4 to 8 week intervals until stability is achieved. This close supervision is necessary for long-term safety and efficacy. Concomitant use with other high-dose Vitamin D or calcium supplements is restricted unless explicitly directed by a healthcare professional. While specific pediatric dosing regimens exist, no automatic adjustment is specified for hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has investigated whether this drug may be an option for managing moderate-to-severe Chronic Pruritus (CP). The drug is a Janus Kinase (JAK) inhibitor, a class of medication studied for its potential influence on inflammatory processes.


1. Core Efficacy and Safety Studies

Studies evaluated whether the drug influenced itch severity and explored its potential effect on the urge to scratch in adult patients with moderate-to-severe Chronic Pruritus. The primary studies involved randomized, double-blind, placebo-controlled trials.

Key Findings on Pruritus:

  • Trial X (Study of effect on itch): The primary endpoint was the proportion of patients who achieved a ge 4-point reduction in the Worst Itch Numeric Rating Scale (WI-NRS) score by Week 16. The study found an association between the drug and reducing the WI-NRS score compared to placebo.
  • Trial Y (Long-term follow-up): This study evaluated sustained changes in symptoms up to Week 52. The long-term follow-up focused on maintaining any observed reduction in itch severity.

2. Effects on Quality of Life and Secondary Symptoms

Secondary analyses investigated the drug's influence on patient-reported outcomes related to quality of life.

Sleep Quality:

Research examined the influence on sleep quality, which is often disturbed by chronic pruritus. The outcomes were measured using a sleep interference score (SIS). The analysis reported an observed effect on SIS scores in patients receiving the drug compared to placebo.

Combination Therapy Research:

A study of combination therapy investigated outcomes in patients receiving the drug alongside a standard topical corticosteroid. The analysis aimed to describe whether the combination influenced the rate of symptom change over the 16-week period.


Safety Profile Notes:

  • The tolerability profile was evaluated in the study population.
  • Studies included people with mild hepatic impairment, and the drug's exposure was evaluated in this group. Studies involving moderate or severe hepatic impairment were not conducted.

Frequently Asked Questions (FAQ)

Common questions about Calvical (FAQ)


Q: How quickly should I expect to see any benefits from taking Calvical?

A: Calvical contains Dihydrotachysterol, which is known to have a longer onset of action compared to other forms of Vitamin D, and effects are typically not instantaneous. Dose adjustments, when necessary, are typically managed at intervals of 4 to 8 weeks, reflecting the time needed to see a stable change in mineral balance.

Q: Does Calvical need to be taken with a meal, or can it be taken on an empty stomach?

A: According to the official product information, the calcium component of Calvical is often recommended to be taken with meals. Taking it with meals is intended to optimize the absorption of the calcium component into your system.

Q: Can long-term use of Calvical cause any unexpected health issues?

A: Regulatory safety information highlights that the primary risk with prolonged use is the potential for significant mineral imbalance. This can lead to serious adverse reactions, such as Hypercalcemic crisis (extremely high blood calcium) and Nephrocalcinosis (calcium deposits in the kidney). Regulatory documents indicate that long-term use warrants careful and consistent medical monitoring.

Q: Is Calvical the type of medication that needs regular blood tests while using it?

A: Yes, regulatory documents emphasize that treatment requires close medical supervision. The dose is managed based on the frequent measurement of serum calcium levels (blood calcium). Monitoring serum calcium levels is a standard procedure used to help ensure safety and manage the dose effectively.

Q: What happens if I accidentally miss a dose of Calvical?

A: General instructions often advise against taking a missed dose if it is almost time for the next scheduled dose. It is generally advised that a double dose should not be taken to make up for a forgotten dose. This general guidance should be supplemented by instructions provided by a healthcare professional.

Q: Can I take other supplements, like magnesium, while I am on Calvical?

A: Official information indicates caution is needed when combining Calvical with other minerals. Specifically, using magnesium-containing products with this Vitamin D analog may increase the risk of elevated magnesium blood levels, especially for individuals with reduced kidney function. Information regarding the use of other supplements should come from a healthcare professional.

Q: Does Calvical have a generic version available, and is it the same?

A: The active ingredient Dihydrotachysterol is available in generic form. In the United States and other regulatory regions, generic versions are required to meet the same strict standards for quality, strength, and performance as the original brand-name product.

Q: What is the typical duration of treatment with Calvical for a specific condition?

A: Treatment with Calvical is typically considered long-term, particularly when managing chronic conditions related to mineral imbalance. The total duration of therapy is not standardized and depends entirely on the specific underlying condition being addressed.

Q: Is Calvical safe for teenagers or adolescents with specific needs?

A: Official regulatory documents state that use in children and adolescents is generally not established or not recommended. If used in this age group, it is done under explicit medical direction with very careful, specialized supervision due to the general lack of established use.

Q: Does Calvical help with muscle cramps or general muscle health?

A: The general purpose of Calvical is to support the body’s overall calcium and mineral balance. Official information states that the correction of calcium and mineral balance supports overall physiological functions, including effective muscle function.

Q: How is the effectiveness of Calvical measured by doctors?

A: The effectiveness of the medication is primarily determined through monitoring serum calcium levels (blood calcium). These measurements are performed to help manage the dose and maintain mineral levels within a target range.

Q: Does Calvical affect the absorption of other vitamins or minerals?

A: Yes, the calcium component of Calvical can potentially reduce the absorption of other orally taken medications. Furthermore, the Vitamin D analog component is specifically included to modulate the body's absorption and use of calcium and phosphate.

Q: Do any common herbs or natural products interact negatively with Calvical?

A: Regulatory documentation notes that certain substances can interact with Calvical. Specifically, Grapefruit Juice is noted to potentially alter the plasma concentrations of the Dihydrotachysterol component. Information on the safety of combining Calvical with other herbs or natural products should be sought from a healthcare professional.

Q: Can Calvical cause temporary headaches or dizziness when first introduced?

A: While not listed as common side effects, headache and dizziness are recognized as potential early symptoms of hypercalcemia (high calcium levels). Since hypercalcemia is a serious side effect, any new occurrence of these symptoms should be reported to a healthcare professional immediately.

Q: Can Calvical affect energy levels or cause fatigue?

A: Fatigue and weakness are noted in regulatory safety documents as potential early symptoms of hypercalcemia (high calcium levels). These symptoms are considered important indicators of potential hypercalcemia that should be reported to a healthcare professional.

Q: Is Calvical effective for people who have very low vitamin D levels?

A: Calvical contains Dihydrotachysterol, a powerful synthetic Vitamin D analog. These analogs are often used when the body's natural Vitamin D activation is compromised, such as in hypoparathyroidism, a condition that may be associated with low active vitamin D levels.

Q: Does Calvical interact with any common antibiotics?

A: Yes, interactions are documented with certain classes of antibiotics. For example, official information requires that oral Tetracyclines (a class of antibiotics) be taken at least 30 minutes to 2 hours apart from Calvical to prevent the calcium component from blocking their absorption.

Q: What happens if Calvical is taken more often than prescribed?

A: Taking more than the prescribed dose increases the risk of serious mineral imbalance and toxicity, including hypercalcemia. Signs of an overdose may include headache, vomiting, and increased thirst or urination. In the event of a suspected overdose, immediate medical assistance is required.

Q: Is the Calvical formulation (tablet, capsule, liquid) important for its effectiveness?

A: The official product information specifies that Calvical is manufactured and intended for use as an oral tablet or capsule. The clinical effectiveness data for other forms, such as a liquid, is not typically included in the regulatory labeling.

Q: Can men use Calvical for conditions typically associated with women?

A: Yes. Calvical is approved for use in the general adult and elderly population, regardless of gender. Its function is to support essential calcium and mineral balance, which is a physiological requirement for both men and women.

How should Calvical be stored and disposed of?

How to Store and Dispose of Calvical

Official regulatory documents define strict conditions for storing and disposing of Calvical (Calcium Carbonate/Dihydrotachysterol Oral Tablet/Capsule).


Storage Requirements

Calvical must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from moisture and excessive heat, and must not be frozen. It is mandatory to store the product in its original container and keep the container tightly closed when not in use. For safety, the product must be kept out of the reach and sight of children at all times.


Disposal Instructions

Expired or unused Calvical must be disposed of properly to prevent environmental contamination. Regulatory guidelines instruct that the medicine must not be flushed down the toilet or poured into a drain. Disposal should be carried out through an authorized drug take-back program or according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calvical found in:

A-Z Index: